Xiaoning Zhang

Xiaoning Zhang

Auto-generated profile, based on publicly available information

Xiaoning Zhang

Department of Neurology The Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University Urumqi China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
LDLei Du
Lei Du
JMJianhua Ma
Jianhua Ma
XZXiaoning Zhang
Xiaoning Zhang

25 October 2018 in Psychogeriatrics
Verified
Journal Article
Closed access
PDF file
LDLei Du
Lei Du
JMJianhua Ma
Jianhua Ma
DHDan He
Dan He
XZXiaoning Zhang
Xiaoning Zhang

1 March 2015 in Journal of Biomedical Nanotechnology
Verified
Journal Article
Closed access
YHYanli Hao
Yanli Hao
LWLan Wang
Lan Wang
JLJun Li
Jun Li
Nan LiuNan Liu
Nan Liu
JFJinfeng Feng
Jinfeng Feng
XZXiaoning Zhang
Xiaoning Zhang
This study aimed to enhance the solubility of a poorly water-soluble drug, pranlukast, as well as its transport across Madin-Darby canine kidney (MDCK) monolayers, thus increasing its oral bioavailability. To accomplish this aim, we prepared a pranlukast-phospholipid complex (PPC). The PPC was prepared by solvent-evaporation and characterized by transmission electron microscopy (TEM), X-ray diffraction (XRD), infrared (IR) spectroscopy, and solubilization studies. The solubility of pranlukast in the PPC was increased from 1.03 ± 0.32 μg/ml to 160.63 ± 2.72 μg/ml with a yield of 96.39 ± 1.20% when the PPC was prepared under optimal conditions. TEM images showed that the PPC particles had a spherical shape. XRD data indicated that pranlukast in the PPC was either in an amorphous form or in a dispersed molecular distribution. IR analysis confirmed the interaction between pranlukast and the phospholipids. The transport mechanism of the PPC and non-complexed pranlukast across MDCK cells was measured and was observed to be significantly greater for the former than for the latter. The in vivo bioavailability of the PPC in rats hastened the onset of pranlukast-induced therapeutic effects, with Cmax and AUC increases of 21.88- and 28.64-fold, respectively, compared with raw crystals. In addition, an in vivo imaging method was used to corroborate that the PPC exhibited rapid circulatory distribution and gastrointestinal tract accumulation. These results indicate that PPC appears to be a promising drug delivery system for pranlukast, improving drug absorption and decreasing side effects by reducing the required oral dose.